Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents

Journal of Psychopharmacology

Volumn 22, Issue 1, 2008, Pages 33-38

  Ojala, Kari ^a,c   Repo Tiihonen, Eila ^a   Tiihonen, Jari ^a,b   Niskanen, Leo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Niuvanniemen sairaala   (Finland)

Author keywords

Antipsychotic agents; Cholesterol; Dyslipidemia; Psychiatric disorders; Statins; Triglycerides

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CLOZAPINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HOSPITAL PATIENT; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL PATIENT; MUSCLE DISEASE; ORGANIC BRAIN SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; WILCOXON SIGNED RANKS TEST;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MENTAL DISORDERS; MIDDLE AGED; TRIGLYCERIDES;

EID: 37749046220     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107077815     Document Type: Article

References (30)

1. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64: 598 - 604
2. Brown S. (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171: 502 - 506
3. Brown S., Hazel I., Barraclough B. (2000) Causes of excess mortality of schizophrenia. Br J Psychiatry 177: 212 - 217
4. Casey D.E. (2004) Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 65 (Suppl 18). 27 - 35
5. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., Lindenmayer J.P., Manoukian S.V., Banerji M.A., Lebovitz H.E., Hennekens C.H. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 (Suppl 7). 4 - 18
6. Correll U.C., Frederickson A.M., Kane J.M., Manu P. (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67: 575 - 583
7. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham I., Mancia G., Cats V.M., Orth-Gomer K., Perk J., Pyorala K., Rodicio J.L., Sans S., Sansoy V., Sechtem U., Silber S., Thomsen T., Wood D. ; Third Joint Force of European and other Societies on Cardiovascular Disease and Prevention in Clinical Practice (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force for European and Other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24: 1601 - 1610
8. Deedwania P.C., Hunninghake D.B., Bays H.E., Jones P.H., Cain V.A., Blasetto J.W. ; STELLAR Study Group (2005) Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 95: 360 - 366
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) High Blood Cholesterol. Third Report of the National Cholesterol Education Program (NCEP) Final Report. National Cholesterol Education Program. National Health, Lung and Blood Institute, National Institute of Health. NIH Publication No. 02-5215.
10. Finnish Society of Internal Medicine (2004) Dyslipidemias. Practical guidelines (Suomen Sisätautilääkärien yhdistys ry:n asettama työryhmä. Dyslipidemiat. Käypä hoito -suositus. In Finnish). Duodecim 120: 1794 - 1816
11. Friday K.E. (2003) Aggressive lipid management for cardiovascular prevention: evidence from clinical trials. Exp Biol Med (Maywood) 228: 769 - 778
12. Friedewald W.T., Levi R.I., Fredrickson D.S. (1972) Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of ultracentrifuge. Clin Chem 18: 499 - 502
13. Furst B.A., Champion K.M., Pierre J.M., Wirshing D.A., Wirshing W.C. (2002) Possible association on QTc interval prolongation with coadministration of quetiapine and lovastatin. Biol Psychiatry 51: 264 - 265
14. Giner V., Munoz R., Redon J. (2002) Risperidone and severe cerivastatininduced rhabdomyolysis. J Intern Med 251: 177 - 178
15. Henderson D.C. (2001) Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 62 (Suppl 23). 39 - 44
16. Henderson D.C., Nguyen D.D., Copeland P.M., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., Freudenreich O., Evins A.E., Cather C., Goff D.C. (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. J Clin Psychiatry 66: 1116 - 1121
17. Jones P.H., Davidson M H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W., STELLAR Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (Stellar trial). Am J Cardiol 92: 152 - 160
18. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., Tang W., Wiener K., Dvorin S., Dietz M.B. (2006) Prevalence of metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163: 1273 - 1276
19. Law M.R., Wald N.J., Rudnicka A.R. (2004) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 326: 1423 - 1427
20. Law M.R., Rudnica A.R. (2006) Statin safety: a systematic review. Am J Cardiol 97: 52 - 60
21. Lindenmayer J., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. (2003) Changes in glucose and cholesterol levels in patients with typical or atypical antipsychotics. Am J Psychiatry 160: 290 - 296
22. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T. Jr, Friedman A., Kleinberg D., Yevich S.J., Davis B., Shon S. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334 - 1349
23. Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNC Drugs 19 (Suppl 1). 1 - 93
24. Newman S.C., Bland R.C. (1991) Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36: 239 - 245
25. Räsänen S., Hakko H., Viilo K., Me yer-Rochow V.B., Moring J. (2003) Excess mortality among long-stay psychiatric patients in Northern Finland. Soc Psychiatry Psychiatr Epidemiol 38: 297 - 304
26. Talbert R.L. (2006) Safety issues with statin therapy. J Am Pharm Assocc 46: 479 - 488
27. Webber M.A., Mahmud W., Lightfoot J.D., Shekhar A. (2004) Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 18: 432 - 434
28. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C. (2002) The effect of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63: 856 - 865
29. Worz C.R., Bottorff M. (2003) Treating dyslipidemic patients with lipid-modifying and combination therapies. Available at http://www.medscape.co/ viewarticle/455750
30. Young I.S. (2005) Lipids for psychiatrists-an overview. J Psychopharmacol 19 (Suppl 6). 66 - 75